P2Y12受容体のノックアウトは,反応性ミクログリアによるニューロンの包装を促進し,プリオン病を加速します
Natallia Makarava1, Tarek Safadi1, Olga Bocharova1
1Department of Neurobiology, University of Maryland School of Medicine, 111 Penn St, Baltimore, MD, 21201, USA.
Journal of neuroinflammation
|August 31, 2025
まとめ
P2Y12受容体は,神経細胞とのマイクログリアル相互作用を調節する. その喪失は正常なコミュニケーションを妨害し,神経細胞の過剰なマイクログリア包帯を促すことで神経変異を加速します.
科学分野:
- 神経科学
- 免疫学
- 細胞生物学
背景:
- P2Y12受容体はホメオスタティックなコミュニケーションに不可欠である.
- 神経変性では,マイクログリアの相互作用が変化し,プロセスの監視から神経のソマ包みへと変化する.
- 慢性神経変性疾患におけるP2Y12の役割はほとんど不明である.
研究 の 目的:
- 健康なモデルとプリオン病のモデルにおけるマイクログリアル形態とニューロン相互作用におけるP2Y12の役割を調査する.
- プリオン病の進行と神経病理学に対する P2Y12 欠失の影響を評価する.
主な方法:
- 成人マウス (健康なマウスとプリオンに感染したマウス) のP2Y12の遺伝子削除
- マイクログリアの形態とマイクログリアとニューロンの相互作用の分析
- プリオン病の進行と神経病理学的変化の評価
主要な成果:
- P2Y12の消去は正常なマイクログリアルプロセスとソマの接触を妨害し,健康なマウスの体と体の相互作用を促した.
- プリオンに感染したマウスでは,P2Y12の喪失により,マイクログリアによる神経包膜が増加し,疾患が加速した.
- 病気の加速はプリオン負荷やニューロン損失とは無関係で,変化したマイクログリアとニューロンの相互作用が悪化を引き起こすことを示唆しています.
結論:
- P2Y12は神経免疫の活性調節体であり ホメオスタティックマーカーではありません
- P2Y12はミクログリアとニューロンのバランスの取れたコミュニケーションを維持し,神経変性における有害なミクログリアの行動を抑制します.
- P2Y12は神経変性疾患の潜在的治療標的である.
関連する概念動画
G-Protein Gated Ion Channels
5.5K
GPCRs are primarily responsible for our sense of smell, taste, and vision. The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory...
Sensory...
5.5K
IP3/DAG Signaling Pathway
12.6K
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
12.6K
Nitric Oxide Signaling Pathway
5.3K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.3K
Ligand-Gated Ion Channel Receptor: Gating Mechanism
4.6K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
4.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
618
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
618


